Prise en charge m??dicale de l??art??riopathie des membres inf??rieurs
- 1 January 1998
- journal article
- abstracts
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 56 (3), 17-23
- https://doi.org/10.2165/00003495-199856003-00003
Abstract
Peripheral arterial disease of the lower limbs is a manifestation of atherosclerosis, and may also affect other vascular territories such as the coronary and cerebral arteries. Progressive narrowing of the vessels up to total occlusion can present as intermittent claudication or pain at rest, with or without cutaneous lesions. Patients with intermittent claudication are at a low risk of amputation, and the symptom has to be regarded as a warning signal for myocardial infarction and stroke. Nevertheless, if the patient's walking distance is too limited to allow a near-normal life, symptomatic treatment to improve quality of life should be considered. Treatment may consist of walking exercise, surgical or interventional radiological revascularisation, or, in some cases, administration of vasoactive drugs. Antiplatelet agents should be administered in an attempt to limit disease progression and prevent cardiac and cerebrovascular complications, together with active measures to reduce established risk factors such as smoking, diabetes, hyperlipidaemia, and arterial hypertension. The presence of pain at rest indicates that a lower limb is jeopardised, especially when the criteria for critical ischaemia have also been met. These criteria include the presence of chronic (lasting for more than 2 weeks) symptoms of ischaemia at rest and a systolic blood pressure less than 50 mm Hg or 30 mm Hg at the ankle or big toe, respectively. In such a situation, revascularisation should be attempted whenever possible. If this is not possible or if the procedure has failed, prostacyclin administered intravenously for days or weeks is an alternative. After revascularisation, early reocclusion may be prevented by administering anticoagulants and late reocclusion by antiplatelet agents, in conjunction with eradication of risk factors. In all situations, therapeutic decision-making should be undertaken in a multidisciplinary setting and should include the following: specialists in angiology (an internist) and interventional radiology; a vascular surgeon; an orthopaedic surgeon, if necessary; and diabetes and infectious disease specialists.Keywords
This publication has 20 references indexed in Scilit:
- Effect of Ticlopidine on the Long-Term Patency of Saphenous-Vein Bypass Grafts in the LegsNew England Journal of Medicine, 1997
- Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limbThe Lancet, 1996
- Age at menopause as a risk factor for cardiovascular mortalityThe Lancet, 1996
- Antithrombotic Therapy in Peripheral Arterial Occlusive DiseaseChest, 1995
- Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.1995
- [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].1995
- Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.1994
- Mortality over a Period of 10 Years in Patients with Peripheral Arterial DiseaseNew England Journal of Medicine, 1992
- Is It Possible to Reduce the Risk of Cardiovascular Events in Subjects Suffering from Intermittent Claudication of the Lower Limbs?Thrombosis and Haemostasis, 1989
- The measured effect of stopping smoking on intermittent claudicationBritish Journal of Surgery, 1982